↓ Skip to main content

Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences

Overview of attention for article published in Targeted Oncology, January 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
30 Mendeley
Title
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
Published in
Targeted Oncology, January 2018
DOI 10.1007/s11523-017-0547-9
Pubmed ID
Authors

Diwakar Davar, Nathan Bahary

Abstract

Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) catalyze the first rate-limiting step in the oxidative metabolism of compounds containing indole rings, including the transformation of the essential amino acid L-tryptophan to N-formyl-L-kynurenine. Through direct and indirect means, IDO exerts both tolerogenic and pro-inflammatory effects and has a profound immunoregulatory role in the tumor microenvironment. Although the role of IDO in mediating peripheral acquired immunologic tolerance has been known for some time, its role in tumorigenesis and the subversion of anti-tumor immunity have only recently been appreciated. Small-molecule inhibitors of IDO1 and TDO are being evaluated as single agents and in combination with immune checkpoint blockade in a host of advanced cancers. In this review, we delineate the tolerogenic and pro-inflammatory effects of IDO as it relates to immune escape and discuss current clinical progress in this area.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 27%
Other 4 13%
Student > Ph. D. Student 3 10%
Student > Bachelor 3 10%
Student > Master 3 10%
Other 2 7%
Unknown 7 23%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 7 23%
Biochemistry, Genetics and Molecular Biology 3 10%
Agricultural and Biological Sciences 3 10%
Chemistry 3 10%
Immunology and Microbiology 3 10%
Other 4 13%
Unknown 7 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2018.
All research outputs
#19,323,874
of 23,923,788 outputs
Outputs from Targeted Oncology
#407
of 571 outputs
Outputs of similar age
#338,189
of 448,179 outputs
Outputs of similar age from Targeted Oncology
#15
of 17 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 571 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,179 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.